| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.
|
Cancer Cell
|
2007
|
12.52
|
|
2
|
Higher versus lower positive end-expiratory pressures in patients with the acute respiratory distress syndrome.
|
N Engl J Med
|
2004
|
11.78
|
|
3
|
Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome.
|
N Engl J Med
|
2006
|
9.52
|
|
4
|
Lower tidal volume ventilation and plasma cytokine markers of inflammation in patients with acute lung injury.
|
Crit Care Med
|
2005
|
5.76
|
|
5
|
Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study.
|
J Clin Oncol
|
2009
|
4.54
|
|
6
|
Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma.
|
J Clin Oncol
|
2010
|
3.43
|
|
7
|
Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study.
|
J Clin Oncol
|
2009
|
3.39
|
|
8
|
Urine IL-18 is an early diagnostic marker for acute kidney injury and predicts mortality in the intensive care unit.
|
J Am Soc Nephrol
|
2005
|
3.38
|
|
9
|
Relative biological effectiveness (RBE) values for proton beam therapy.
|
Int J Radiat Oncol Biol Phys
|
2002
|
3.21
|
|
10
|
Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping.
|
Oncologist
|
2011
|
3.05
|
|
11
|
A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients.
|
Cancer Res
|
2009
|
3.00
|
|
12
|
Excess body weight is not independently associated with outcome in mechanically ventilated patients with acute lung injury.
|
Ann Intern Med
|
2004
|
2.80
|
|
13
|
Acute kidney injury in patients with acute lung injury: impact of fluid accumulation on classification of acute kidney injury and associated outcomes.
|
Crit Care Med
|
2011
|
2.55
|
|
14
|
Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy.
|
Proc Natl Acad Sci U S A
|
2012
|
2.50
|
|
15
|
Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion.
|
Cancer Res
|
2011
|
2.40
|
|
16
|
Racial and ethnic disparities in mortality from acute lung injury.
|
Crit Care Med
|
2009
|
2.14
|
|
17
|
Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation.
|
Proc Natl Acad Sci U S A
|
2013
|
2.14
|
|
18
|
Accelerated partial breast irradiation with low-dose-rate interstitial implant brachytherapy after wide local excision: 12-year outcomes from a prospective trial.
|
Int J Radiat Oncol Biol Phys
|
2011
|
2.06
|
|
19
|
A simple clinical predictive index for objective estimates of mortality in acute lung injury.
|
Crit Care Med
|
2009
|
1.91
|
|
20
|
Use of sedatives, opioids, and neuromuscular blocking agents in patients with acute lung injury and acute respiratory distress syndrome.
|
Crit Care Med
|
2008
|
1.71
|
|
21
|
Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer.
|
Cancer Res
|
2009
|
1.64
|
|
22
|
Association of physical examination with pulmonary artery catheter parameters in acute lung injury.
|
Crit Care Med
|
2009
|
1.55
|
|
23
|
TGF-β blockade improves the distribution and efficacy of therapeutics in breast carcinoma by normalizing the tumor stroma.
|
Proc Natl Acad Sci U S A
|
2012
|
1.51
|
|
24
|
Recovery rate and prognosis in older persons who develop acute lung injury and the acute respiratory distress syndrome.
|
Ann Intern Med
|
2002
|
1.49
|
|
25
|
Paclitaxel decreases the interstitial fluid pressure and improves oxygenation in breast cancers in patients treated with neoadjuvant chemotherapy: clinical implications.
|
J Clin Oncol
|
2005
|
1.48
|
|
26
|
Secondary carcinogenesis in patients treated with radiation: a review of data on radiation-induced cancers in human, non-human primate, canine and rodent subjects.
|
Radiat Res
|
2007
|
1.44
|
|
27
|
POINT: Operative risk of pneumonectomy--influence of preoperative induction therapy.
|
J Thorac Cardiovasc Surg
|
2009
|
1.39
|
|
28
|
Survival after brain metastases from breast cancer in the trastuzumab era.
|
J Clin Oncol
|
2005
|
1.36
|
|
29
|
Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma.
|
Clin Cancer Res
|
2014
|
1.33
|
|
30
|
Neuroendocrine tumors of the sinonasal tract. Results of a prospective study incorporating chemotherapy, surgery, and combined proton-photon radiotherapy.
|
Cancer
|
2002
|
1.30
|
|
31
|
Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer.
|
Oncologist
|
2010
|
1.23
|
|
32
|
Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma.
|
Neuro Oncol
|
2013
|
1.16
|
|
33
|
A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer.
|
Clin Cancer Res
|
2013
|
1.16
|
|
34
|
Efficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: a phase II study.
|
Clin Cancer Res
|
2013
|
1.16
|
|
35
|
A safety and survival analysis of neoadjuvant bevacizumab with standard chemoradiation in a phase I/II study compared with standard chemoradiation in locally advanced rectal cancer.
|
Oncologist
|
2010
|
1.11
|
|
36
|
Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer.
|
PLoS One
|
2012
|
1.05
|
|
37
|
Diffuse large B-cell lymphoma of bone: an analysis of differentiation-associated antigens with clinical correlation.
|
Am J Surg Pathol
|
2003
|
1.03
|
|
38
|
Effects of sorafenib on intra-tumoral interstitial fluid pressure and circulating biomarkers in patients with refractory sarcomas (NCI protocol 6948).
|
PLoS One
|
2012
|
1.03
|
|
39
|
Phase II study of neoadjuvant bevacizumab and radiotherapy for resectable soft tissue sarcomas.
|
Int J Radiat Oncol Biol Phys
|
2010
|
1.02
|
|
40
|
Magnetic resonance imaging biomarkers in hepatocellular carcinoma: association with response and circulating biomarkers after sunitinib therapy.
|
J Hematol Oncol
|
2013
|
0.97
|
|
41
|
Tolerability of combined modality therapy for rectal cancer in elderly patients aged 75 years and older.
|
Int J Radiat Oncol Biol Phys
|
2011
|
0.96
|
|
42
|
Exploratory analysis of early toxicity of sunitinib in advanced hepatocellular carcinoma patients: kinetics and potential biomarker value.
|
Clin Cancer Res
|
2010
|
0.96
|
|
43
|
Radiation dose escalation in limited-stage small-cell lung cancer.
|
Int J Radiat Oncol Biol Phys
|
2003
|
0.92
|
|
44
|
Dye-enhanced multimodal confocal imaging as a novel approach to intraoperative diagnosis of brain tumors.
|
Brain Pathol
|
2012
|
0.92
|
|
45
|
Biomarkers of antiangiogenic therapy: how do we move from candidate biomarkers to valid biomarkers?
|
J Clin Oncol
|
2009
|
0.92
|
|
46
|
Lung dose-volume parameters and the risk of pneumonitis for patients treated with accelerated partial-breast irradiation using three-dimensional conformal radiotherapy.
|
J Clin Oncol
|
2009
|
0.92
|
|
47
|
Proton stereotactic radiotherapy for persistent adrenocorticotropin-producing adenomas.
|
J Clin Endocrinol Metab
|
2007
|
0.91
|
|
48
|
A single-nucleotide polymorphism in the methylene tetrahydrofolate reductase (MTHFR) gene is associated with risk of radiation pneumonitis in lung cancer patients treated with thoracic radiation therapy.
|
Cancer
|
2011
|
0.90
|
|
49
|
Dose--volume effects on patient-reported acute gastrointestinal symptoms during chemoradiation therapy for rectal cancer.
|
Int J Radiat Oncol Biol Phys
|
2012
|
0.90
|
|
50
|
Proton stereotactic radiosurgery in management of persistent acromegaly.
|
Endocr Pract
|
2008
|
0.90
|
|
51
|
Outcomes and tolerability of chemoradiation therapy for pancreatic cancer patients aged 75 years or older.
|
Int J Radiat Oncol Biol Phys
|
2009
|
0.90
|
|
52
|
External beam accelerated partial-breast irradiation using 32 gy in 8 twice-daily fractions: 5-year results of a prospective study.
|
Int J Radiat Oncol Biol Phys
|
2012
|
0.89
|
|
53
|
Potential of 18F-FDG PET toward personalized radiotherapy or chemoradiotherapy in lung cancer.
|
Eur J Nucl Med Mol Imaging
|
2013
|
0.88
|
|
54
|
Safety, Efficacy, and Biomarker Exploration in a Phase II Study of Bevacizumab, Oxaliplatin, and Gemcitabine in Recurrent Müllerian Carcinoma.
|
Clin Ovarian Cancer Other Gynecol Malig
|
2011
|
0.87
|
|
55
|
Evolution of oxygen and glucose concentration profiles in a tissue-mimetic culture system of embryonic stem cells.
|
Ann Biomed Eng
|
2006
|
0.87
|
|
56
|
Twice-daily radiotherapy as concurrent boost technique during two chemotherapy cycles in neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: mature results of phase II study.
|
Int J Radiat Oncol Biol Phys
|
2004
|
0.85
|
|
57
|
Uveal melanoma recurrence after fractionated proton beam therapy: comparison of survival in patients treated with reirradiation or with enucleation.
|
Int J Radiat Oncol Biol Phys
|
2010
|
0.83
|
|
58
|
Outcomes after radiation therapy with concurrent weekly platinum-based chemotherapy or every-3-4-week 5-fluorouracil-containing regimens for squamous cell carcinoma of the vulva.
|
Gynecol Oncol
|
2010
|
0.81
|
|
59
|
Proton beam radiosurgery for vestibular schwannoma: tumor control and cranial nerve toxicity.
|
Neurosurgery
|
2003
|
0.81
|
|
60
|
Natural history and role of radiation in patients with supratentorial and infratentorial WHO grade II ependymomas: results from a population-based study.
|
J Neurooncol
|
2013
|
0.81
|
|
61
|
Underutilization of radiation therapy in patients with glioblastoma: predictive factors and outcomes.
|
Cancer
|
2013
|
0.79
|
|
62
|
Circulating tumor cells as predictors of response and failure in breast cancer patients treated with preoperative chemotherapy.
|
Int J Biol Markers
|
2013
|
0.79
|
|
63
|
Steroid treatment for persistent ARDS: a word of caution.
|
Crit Care
|
2007
|
0.78
|
|
64
|
Anti-VEGFR-3 therapy and lymph node metastasis [corrected].
|
Cancer Res
|
2007
|
0.75
|
|
65
|
Towards the development of an error checker for radiotherapy treatment plans: a preliminary study.
|
Phys Med Biol
|
2007
|
0.75
|